These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 7622309)
1. c-erbB growth-factor-receptor proteins in ovarian tumours. Simpson BJ; Phillips HA; Lessells AM; Langdon SP; Miller WR Int J Cancer; 1995 Jun; 64(3):202-6. PubMed ID: 7622309 [TBL] [Abstract][Full Text] [Related]
2. c-erbB-3 protein expression in ovarian tumours. Simpson BJ; Weatherill J; Miller EP; Lessells AM; Langdon SP; Miller WR Br J Cancer; 1995 Apr; 71(4):758-62. PubMed ID: 7710941 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary. Wang DP; Konishi I; Koshiyama M; Nanbu Y; Iwai T; Nonogaki H; Mori T; Fujii S Virchows Arch A Pathol Anat Histopathol; 1992; 421(5):393-400. PubMed ID: 1360720 [TBL] [Abstract][Full Text] [Related]
4. Expression of the ErbB family of receptors in ovarian cancer. Scoccia B; Lee YM; Niederberger C; Ilekis JV J Soc Gynecol Investig; 1998; 5(3):161-5. PubMed ID: 9614647 [TBL] [Abstract][Full Text] [Related]
5. Type 1 protein tyrosine kinases in benign and malignant breast lesions. Suo Z; Emilsen E; Tveit KM; Nesland JM Histopathology; 1998 Dec; 33(6):514-21. PubMed ID: 9870145 [TBL] [Abstract][Full Text] [Related]
6. Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer. Berns EM; Klijn JG; Henzen-Logmans SC; Rodenburg CJ; van der Burg ME; Foekens JA Int J Cancer; 1992 Sep; 52(2):218-24. PubMed ID: 1325950 [TBL] [Abstract][Full Text] [Related]
7. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. van Dam PA; Vergote IB; Lowe DG; Watson JV; van Damme P; van der Auwera JC; Shepherd JH J Clin Pathol; 1994 Oct; 47(10):914-9. PubMed ID: 7962604 [TBL] [Abstract][Full Text] [Related]
8. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. Mellon K; Thompson S; Charlton RG; Marsh C; Robinson M; Lane DP; Harris AL; Horne CH; Neal DE J Urol; 1992 Feb; 147(2):496-9. PubMed ID: 1370701 [TBL] [Abstract][Full Text] [Related]
9. The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Gullick WJ; Srinivasan R Breast Cancer Res Treat; 1998; 52(1-3):43-53. PubMed ID: 10066071 [TBL] [Abstract][Full Text] [Related]
10. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Travis A; Pinder SE; Robertson JF; Bell JA; Wencyk P; Gullick WJ; Nicholson RI; Poller DN; Blamey RW; Elston CW; Ellis IO Br J Cancer; 1996 Jul; 74(2):229-33. PubMed ID: 8688326 [TBL] [Abstract][Full Text] [Related]
11. Frequent immunohistochemical detection of EGF supergene family members in ovarian carcinogenesis. Stromberg K; Johnson GR; O'Connor DM; Sorensen CM; Gullick WJ; Kannan B Int J Gynecol Pathol; 1994 Oct; 13(4):342-7. PubMed ID: 7814196 [TBL] [Abstract][Full Text] [Related]
13. Immunolocalization of epidermal growth factor receptor and c-erbB-2 oncogene product in human ovarian carcinoma. Ito K; Sasano H; Ozawa N; Sato S; Silverberg SG; Yajima A Int J Gynecol Pathol; 1992 Oct; 11(4):253-7. PubMed ID: 1356938 [TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor and c-erbB-2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms. Harlozińska A; Bar JK; Sobańska E; Goluda M Tumour Biol; 1998; 19(5):364-73. PubMed ID: 9701727 [TBL] [Abstract][Full Text] [Related]
15. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. Fléjou JF; Paraf F; Muzeau F; Fékété F; Hénin D; Jothy S; Potet F J Clin Pathol; 1994 Jan; 47(1):23-6. PubMed ID: 7907608 [TBL] [Abstract][Full Text] [Related]
16. c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Quinn CM; Ostrowski JL; Lane SA; Loney DP; Teasdale J; Benson FA Histopathology; 1994 Sep; 25(3):247-52. PubMed ID: 7821892 [TBL] [Abstract][Full Text] [Related]
17. The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study. van der Burg ME; Henzen-Logmans SC; Foekens JA; Berns EM; Rodenburg CJ; van Putten WL; Klijn JG Eur J Cancer; 1993; 29A(14):1951-7. PubMed ID: 8280488 [TBL] [Abstract][Full Text] [Related]
18. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. Meden H; Marx D; Raab T; Kron M; Schauer A; Kuhn W J Obstet Gynaecol (Tokyo 1995); 1995 Apr; 21(2):167-78. PubMed ID: 8556578 [TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of TGF-alpha, EGF-R, c-erbB-2, c-H-ras, c-myc, estrogen and progesterone in benign and malignant human breast lesions: a concomitant expression. Spaventi R; Kamenjicki E; Pecina N; Grazio S; Grazio S; Pavelic J; Kusic B; Cvrtila D; Danilovic Z; Spaventi S In Vivo; 1994; 8(2):183-9. PubMed ID: 7919121 [TBL] [Abstract][Full Text] [Related]
20. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors. Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]